Department of Pharmaceutical, The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Department of Puberty Gynecology, Shenzhen Children's Hospital, Shenzhen, Guangdong, China.
J Cancer Res Ther. 2024 Apr 1;20(2):684-694. doi: 10.4103/jcrt.jcrt_134_23. Epub 2024 Apr 30.
Gypenoside (Gyp) is easily degraded in the gastrointestinal tract, resulting in its low bioavailability. We aimed to develop a tumor-targeted Gyp nanodrug delivery system and to investigate its antitumor effect in vitro.
We used Gyp as the therapeutic drug molecule, mesoporous silica (MSN) and liposome (Lipo) as the drug carrier and protective layers, and aptamer SYL3C as the targeting element to establish a tumor-targeted nanodrug delivery system (i.e., SYL3C-Lipo@Gyp-MSN). The characteristics of SYL3C-Lipo@Gyp-MSN were investigated, and its drug release performance, cell uptake, and antitumor activity in vitro were evaluated.
A tumor-targeted Gyp nanodrug delivery system was successfully prepared. The SYL3C-Lipo@Gyp-MSN was spherical or ellipsoidal; had good dispersion, which enabled it to specifically target and kill the liver tumor cell HepG2; and effectively protected the early leakage of Gyp.
We have established a tumor-targeted nanodrug delivery system that can target and kill liver cancer cells and may provide a strategy for preparing new nanodrug-loaded preparations of traditional Chinese medicine.
绞股蓝苷(Gyp)在胃肠道中容易降解,导致其生物利用度低。本研究旨在开发一种肿瘤靶向的绞股蓝苷纳米药物递送系统,并在体外研究其抗肿瘤作用。
以绞股蓝苷为治疗药物分子,介孔硅(MSN)和脂质体(Lipo)为药物载体和保护层,适配体 SYL3C 为靶向元件,构建肿瘤靶向纳米药物递送系统(即 SYL3C-Lipo@Gyp-MSN)。考察了 SYL3C-Lipo@Gyp-MSN 的性质,评价了其体外释药性能、细胞摄取和抗肿瘤活性。
成功制备了肿瘤靶向绞股蓝苷纳米药物递送系统。SYL3C-Lipo@Gyp-MSN 呈球形或椭圆形,分散性良好,能够特异性地靶向和杀伤肝癌细胞 HepG2,并能有效保护绞股蓝苷的早期泄漏。
本研究建立了一种肿瘤靶向纳米药物递送系统,能够靶向杀伤肝癌细胞,为制备新型中药纳米载药制剂提供了策略。